Bioventus (BVS) Cash from Investing Activities (2020 - 2026)
Bioventus (BVS) posted Cash from Investing Activities of -$574000.0 for Q1 2026, up 1.03% on a QoQ basis from -$580000.0 in Q4 2025, and up 30.51% year-over-year from -$439818.2 in Q1 2025.
Bioventus (BVS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Bioventus' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$574000.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 30.51% year-over-year to -$574000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.0 million (down 112.95% YoY) and the FY2025 annual result came in at -$3.2 million, down 114.14% from the prior year.
- Cash from Investing Activities was -$574000.0 for Q1 2026 at Bioventus, up from -$580000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $45.0 million in Q3 2023 and bottomed at -$56.3 million in Q4 2022.
- A 5-year average of -$4.1 million and a median of -$826000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 1864.69% — and 2024, when it soared 4178.51%.
- Bioventus' Cash from Investing Activities stood at -$3.4 million in 2022, then surged by 82.63% to -$591000.0 in 2023, then surged by 4178.51% to $24.1 million in 2024, then tumbled by 102.41% to -$580000.0 in 2025, then climbed by 1.03% to -$574000.0 in 2026.
- Business Quant data shows BVS's Cash from Investing Activities at -$574000.0 in Q1 2026, -$580000.0 in Q4 2025, and -$473000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.40 Bn | 176.11 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.93 Bn | 126.05 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.35 Bn | 99.13 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.71 Bn | 67.25 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.68 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.04 Bn | 25.76 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Bioventus | 826.74 Mn | 790.89 Mn | 90.77 Mn | -574,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -574,000.00 |
| Mar 28, 2026 | -574,000.00 |
| Dec 31, 2025 | -580,000.00 |
| Dec 31, 2025 | -580,000.00 |
| Sep 27, 2025 | -473,000.00 |
| Sep 27, 2025 | -473,000.00 |
| Jun 28, 2025 | -1.37 Mn |
| Jun 28, 2025 | -1.37 Mn |
| Mar 29, 2025 | -826,000.00 |
| Mar 29, 2025 | -826,000.00 |
| Dec 31, 2024 | 24.10 Mn |
| Dec 31, 2024 | 24.10 Mn |
| Sep 28, 2024 | -64,000.00 |
| Sep 28, 2024 | -64,000.00 |
| Jun 29, 2024 | -77,000.00 |
| Jun 29, 2024 | -77,000.00 |
| Mar 30, 2024 | -1.00 Mn |
| Mar 30, 2024 | -1.00 Mn |
| Dec 31, 2023 | -591,000.00 |
| Dec 31, 2023 | -591,000.00 |